PDSB
PDS Biotechnology Corp
$1.05
-6.25%
$58.6M
No data for this timeframe.
Vol
Market Cap$58.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders17 funds
Inst. Value$2.1M
Inst. Activity0 buys / 1 sells
Reddit Sentiment56° Neutral
SEC Reports6
Press Releases3
Recent Activity
Jun 9, 2026
short_volume
Short Volume: PDSB — 61.1% short (0.3M / 0.5M)
Short: 327,324 | Exempt: 1,753 | TRF Vol: 535,574 | Short Ratio: 61.1% | Off-exchange volume (dark p
Jun 2, 2026
SEC
PDS Biotechnology Corp received a Nasdaq notice on June 2, 2026 confirming it has regained compliance with the $1.00 min
8-K — Impact 5/10
May 13, 2026
SEC
PDS Biotech reported Q1 2026 net loss of $7.3M ($0.13/share), narrower than the $8.5M loss ($0.21/share) in Q1 2025, dri
PRESS-RELEASE — Impact 5/10
May 1, 2026
SEC
PDS Biotechnology entered a $6M promissory note with YA II PN, LTD (10% interest, 12-month maturity) and issued a warran
8-K — Impact 6/10
Jan 12, 2026
Insider
BEDU-ADDO FRANK was granted 548,782 shares
President/CEO
Jan 12, 2026
Insider
CONN GREGORY was granted 150,000 shares
Chief Scientific Officer
Jan 12, 2026
Insider
Shepard Kirk V. was granted 300,000 shares
Chief Medical Officer
Inst.
COMMONWEALTH EQUITY SERVICES, LLC — TRIM
90,797 shares ($54.9K)
Price Targets
$7.50
+614.3% upside
Strong Buy
Current $1.05
Low $3.00
Median $4.50
High $15.00
3 analysts
$3.00
$15.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 15, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.13 ▲ +12.6% | $-0.14 — $-0.12 | 40% YoY | 3 |
| Next Q | $-0.12 ▲ +16.7% | $-0.15 — $-0.10 | 39% YoY | 3 |
| Current FY | $-0.50 ▲ +9.1% | $-0.60 — $-0.44 | 33% YoY | 3 |
| Next FY | $-0.47 ▲ +13.0% | $-0.61 — $-0.39 | 6% YoY | 3 |
Latest Reports
BULLISH
8-K
5/10
PDS Biotechnology Corp received a Nasdaq notice on June 2, 2026 confirming it has regained compliance with the $1.00 min
Jun 2, 2026
NEUTRAL
PRESS-RELEASE
5/10
PDS Biotech reported Q1 2026 net loss of $7.3M ($0.13/share), narrower than the $8.5M loss ($0.21/share) in Q1 2025, dri
May 13, 2026
BULLISH
Press
8/10
PDS Biotechnology announced preliminary data from a trial using its PDS01ADC technology, showing a 78% objective respons
Apr 15, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $986.8K | — |
| BlackRock, Inc. | $335.2K | — |
| VANGUARD FIDUCIARY TRUST CO | $185.9K | — |
| BLAIR WILLIAM & CO/IL | $181.5K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jan 12, 2026 | BEDU-ADDO FRANK | A | $0.00 |
| Jan 12, 2026 | CONN GREGORY | A | $0.00 |
| Jan 12, 2026 | Shepard Kirk | A | $0.00 |
| Jan 12, 2026 | Boesgaard Lars | A | $0.00 |
| Jan 12, 2026 | Brown Spencer | A | $0.00 |
Reddit Sentiment
56°
Neutral
Bearish
Neutral
Bullish
17 institutional holders with $2.1M total value (3,441,240 shares) as of 2026-Q1. Top holders: ROYAL, VANGUARD, BlackRock,. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 75 | $0.00 | 0.0% | DOUBLED +2380.6% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1,631,089 | $986.8K | 47.4% | — |
| 3 | BlackRock, Inc. | 554,048 | $335.2K | 16.1% | — |
| 4 | VANGUARD FIDUCIARY TRUST CO | 307,311 | $185.9K | 8.9% | — |
| 5 | BLAIR WILLIAM & CO/IL | 300,000 | $181.5K | 8.7% | ADD +63.3% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 220,800 | $133.6K | 6.4% | TRIM -35.9% |
| 7 | STATE STREET CORP | 133,333 | $80.7K | 3.9% | — |
| 8 | WELLS FARGO & COMPANY/MN | 110,500 | $66.9K | 3.2% | — |
| 9 | COMMONWEALTH EQUITY SERVICES, LLC | 90,797 | $54.9K | 2.6% | TRIM -53.9% |
| 10 | Rockefeller Capital Management L.P. | 27,664 | $16.7K | 0.8% | TRIM -25.5% |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 22,052 | $13.3K | 0.6% | — |
| 12 | Vanguard Global Advisers, LLC | 12,546 | $7.6K | 0.4% | — |
| 13 | CITADEL ADVISORS LLC | 11,300 | $6.8K | 0.3% | ADD +55.2% |
| 14 | RAYMOND JAMES FINANCIAL INC | 10,236 | $6.2K | 0.3% | — |
| 15 | MORGAN STANLEY | 3,922 | $2.4K | 0.1% | TRIM -40.4% |
| 16 | GROUP ONE TRADING LLC | 3,567 | $2.2K | 0.1% | — |
| 17 | JONES FINANCIAL COMPANIES LLLP | 2,000 | $1.1K | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| COMMONWEALTH EQUITY SERVICES, LLC | TRIM | 196,797 | 90,797 | -53.9% | $54.9K | 2026-Q1 |
| COMMONWEALTH EQUITY SERVICES, LLC | DOUBLED | 90,497 | 196,797 | +117.5% | $151.5K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 275,861 | 176,700 | -35.9% | $136.0K | 2025-Q4 |
| Rockefeller Capital Management L.P. | TRIM | 34,467 | 25,664 | -25.5% | $19.8K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 8,259 | 4,922 | -40.4% | $3.8K | 2025-Q4 |
| CITADEL ADVISORS LLC | ADD | 249,025 | 386,430 | +55.2% | $390.3K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 105,687 | 275,861 | +161.0% | $278.6K | 2025-Q3 |
| UBS Group AG | TRIM | 543,021 | 200,236 | -63.1% | $202.2K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 648 | 1,037 | +60.0% | $1.0K | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 1,510,221 | 1,951,343 | +29.2% | $2.6M | 2025-Q2 |
| UBS Group AG | DOUBLED | 251,156 | 543,021 | +116.2% | $722.2K | 2025-Q2 |
| Vanguard Personalized Indexing Management, LLC | TRIM | 28,523 | 13,979 | -51.0% | $18.6K | 2025-Q2 |
| ROYAL BANK OF CANADA | DOUBLED | 288 | 7,144 | +2380.6% | $9.0K | 2025-Q2 |
| ROYAL BANK OF CANADA | NEAR_EXIT | 1,490 | 288 | -80.7% | — | 2025-Q1 |
| BLAIR WILLIAM & CO/IL | ADD | 157,500 | 257,200 | +63.3% | $306.1K | 2025-Q1 |
| UBS Group AG | DOUBLED | 50,058 | 251,156 | +401.7% | $298.9K | 2025-Q1 |
| FMR LLC | DOUBLED | 847 | 2,778 | +228.0% | $3.3K | 2025-Q1 |
| BLAIR WILLIAM & CO/IL | ADD | 121,743 | 157,500 | +29.4% | $256.7K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 23,200 | 100,000 | +331.0% | $163.0K | 2024-Q4 |
| UBS Group AG | DOUBLED | 20,234 | 50,058 | +147.4% | $81.6K | 2024-Q4 |
| MARSHALL WACE, LLP | ADD | 28,187 | 39,024 | +38.4% | $63.6K | 2024-Q4 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 25,298 | 18,390 | -27.3% | $30.0K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 27,432 | 17,894 | -34.8% | $29.2K | 2024-Q4 |
| ROYAL BANK OF CANADA | TRIM | 2,592 | 1,490 | -42.5% | $2.0K | 2024-Q4 |
| FMR LLC | TRIM | 2,209 | 847 | -61.7% | $1.4K | 2024-Q4 |
11 unique insiders with 11 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 12, 2026 | BEDU-ADDO FRANK | President/CEO | AWARD | 548,782 | — | — |
| Jan 12, 2026 | CONN GREGORY | Chief Scientific Officer | AWARD | 150,000 | — | — |
| Jan 12, 2026 | Shepard Kirk V. | Chief Medical Officer | AWARD | 300,000 | — | — |
| Jan 12, 2026 | Boesgaard Lars | Chief Financial Officer | AWARD | 300,000 | — | — |
| Jan 12, 2026 | Brown Spencer D. | Senior VP, General Counsel | AWARD | 300,000 | — | — |
| Jan 12, 2026 | Toutain Stephan | Chief Operating Officer | AWARD | 300,000 | — | — |
| Jan 12, 2026 | Freitag Gregory Gene | Director | AWARD | 54,876 | — | — |
| Jan 12, 2026 | Iliev Ilian | Director | AWARD | 54,876 | — | — |
| Jan 12, 2026 | Ali-Jackson Kamil | Director | AWARD | 54,876 | — | — |
| Jan 12, 2026 | BRAWLEY OTIS W | Director | AWARD | 54,876 | — | — |
| Jan 12, 2026 | Glover Stephen C. | Director | AWARD | 54,876 | — | — |
6 SEC filing reports analyzed. Sentiment: 3 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 5.7/10.
BULLISH
8-K
5/10
PDS Biotechnology Corp received a Nasdaq notice on June 2, 2026 confirming it has regained complianc
Jun 2, 2026
NEUTRAL
PRESS-RELEASE
5/10
PDS Biotech reported Q1 2026 net loss of $7.3M ($0.13/share), narrower than the $8.5M loss ($0.21/sh
May 13, 2026
BEARISH
8-K
6/10
PDS Biotechnology entered a $6M promissory note with YA II PN, LTD (10% interest, 12-month maturity)
May 1, 2026
NEUTRAL
S-3/A
4/10
PDS Biotechnology Corp filed an S-3/A shelf registration statement, authorizing the potential issuan
Apr 27, 2026
BULLISH
8-K
6/10
PDS Biotechnology updated its corporate presentation deck, which includes positive clinical trial da
Apr 24, 2026
BULLISH
8-K
8/10
PDS Biotechnology announced positive interim Phase 2 clinical trial data for its drug PDS01ADC in tr
Apr 15, 2026
BULLISH
8/10
PDS Biotechnology announced preliminary data from a trial using its PDS01ADC technology, showing a 7
Apr 15, 2026
MIXED
6/10
PDS Biotechnology reported financial results for 2025 and provided a clinical update, including a Ph
Mar 30, 2026
NEUTRAL
3/10
PDS Biotechnology announced it will report its Q4 and full-year 2025 financial results and provide a
Mar 24, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.50 mean target
+614.3% upside
Strong Buy (3.00)
$3.00 Low
$15.00 High
| Metric | Value |
|---|---|
| Current Price | $1.05 |
| Target Low | $3.00 |
| Target Mean | $7.50 |
| Target Median | $4.50 |
| Target High | $15.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.13 | $-0.14 | $-0.12 | 39.7% | +12.6% | — | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.12 | $-0.15 | $-0.10 | 38.6% | +16.7% | — | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-0.50 | $-0.60 | $-0.44 | 32.9% | +9.1% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-0.47 | $-0.61 | $-0.39 | 6.0% | +13.0% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.127 | |
| 7d ago | $-0.145 | +0.018 |
| 30d ago | $-0.145 | +0.018 |
| 60d ago | $0.000 | -0.127 |
| 90d ago | $-0.180 | +0.053 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 15, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
56°
Neutral
Bearish
Neutral
Bullish
5 mentions
2 bullish
1 bearish
5 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 8, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 8, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 8, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 8, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Feb 20, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
PDSB: Steady Progress in Cancer Immunotherapy
▲ 1
💬 1
⚡ 0.5
Open Discussion on PDSB
▲ 1
💬 1
⚡ 0.5
Jun 9, 2026
short_volume
Short Volume: PDSB — 61.1% short (0.3M / 0.5M)
Short: 327,324 | Exempt: 1,753 | TRF Vol: 535,574 | Short Ratio: 61.1% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
<p align="center"><em>Investor Webcast Scheduled for 8:00 am ET</em></p>
May 13, 2026
earnings_calendar
PDSB Q1 2026 Earnings Scheduled — 2026-05-13
Apr 15, 2026
announcement
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
<p align="center"><em>78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR </em><em>2-year survival rate of &g
Apr 10, 2026
short_volume
Short Volume: PDSB — 67.0% short (0.4M / 0.6M)
Short: 416,782 | Exempt: 144 | TRF Vol: 621,963 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_volume
Short Volume: PDSB — 64.9% short (0.6M / 1.0M)
Short: 647,576 | Exempt: 12,735 | TRF Vol: 998,461 | Short Ratio: 64.9% | Off-exchange volume (dark pool + OTC)
Mar 31, 2026
short_volume
Short Volume: PDSB — 68.6% short (0.4M / 0.5M)
Short: 356,718 | Exempt: 0 | TRF Vol: 519,959 | Short Ratio: 68.6% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
earnings
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement
<p align="center"><em>Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs</em></p
Mar 30, 2026
earnings_calendar
PDSB Q4 2025 Earnings After Market Close — 2026-03-30
Mar 26, 2026
earnings_calendar
PDSB Q4 2025 Earnings After Market Close — 2026-03-26
Mar 24, 2026
earnings
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
<p align="justify">PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”)